Takeda Will Import 50 Million Doses of Moderna’s COVID-19 Vaccine

October 30, 2020

Japanese drugmaker Takeda has announced plans to distribute 50 million doses of Moderna’s COVID-19 vaccine candidate, mRNA-1273, in Japan.

Under the agreement, the first shipment is expected to arrive during the first quarter of 2021, and Takeda will seek approval from Japan’s Pharmaceuticals and Medical Devices Agency.

The vaccine is currently in a phase 3 clinical trial in the U.S., testing to evaluate its efficacy vs. a placebo in 30,000 participants.

Moderna said it expects to have enough supporting data to apply for an Emergency Use Authorization from the FDA by late November.

View today's stories